This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish (read more).

News

Expansion of Controlled Substance Storage to Support Blister Packaging Capacity for Opioids

PCI stands ready to support packaging changes brought in by new Opioid legislation

PCI Is pleased to announce further investment in our expansive infrastructure for packaging of controlled substances, complementing our industry-leading capacity for blister packaging, a key tenet of recent calls for dispensing opioid prescriptions in limited quantity unit dose packaging as a tactic to combat substance misuse.

We have extended onsite controlled substance storage at our US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for these specialized requirements. PCI supports DEA Schedule I-V controlled substances for both commercial prescription medicines, as well as those for investigational clinical trials, with approximately two million square feet of dedicated packaging infrastructure across the two locations.

Child resistant unit dose blister packaging has been a key focus of discussion in US opioid reform measures. A trusted outsourcing partner to the pharmaceutical industry, We feature immediate capacity for the introduction of new unit dose blister packaging in formats conducive to meeting the stringent child resistant requirements required by opioids. Specializing in new product introductions, our extensive capacity positions us to support more than five billion unit dose blister packs annually.

There has been considerable discussion about the opportunity for utilizing blister packaging as one tool to positively influence the misuse of opioid and pain management medications in the US,” noted Phil DiGiacomo, Senior Vice President of Sales & Marketing at PCI. “A critical factor in that narrative is to ensure safety in the home. Opioid packaging demands the highest levels of child resistance. PCI is in a unique position to make this specialized packaging immediately available by virtue of our proven, highly automated, high-speed solutions, helping our pharmaceutical clients in their transition to meet the latest legislative requirements. These child resistant packaging solutions protect younger people in the home, and provide an adherence platform supporting the user to take medication as prescribed.

January 21, 2019


Expansion of High Potent Tableting and Powder Modification Capacity

Investment in new technologies at PCI’s global manufacturing Center of Excellence in Tredegar, Wales, to double highly potent tableting capacity... View Article

PCI Welcomes New Chief Financial Officer and SVP, Serge Dupuis

PCI is pleased to welcome Serge Dupuis as Senior Vice President and Chief Financial Officer. Serge’s appointment supports PCI’s continued... View Article

x